Amethyst Radiotherapy Secures €300m in Financing from Ares Management to Accelerate Growth Across Europe

Amsterdam, June 12th 2024 – In a significant stride towards enhancing access to advanced cancer treatment, Amethyst Radiotherapy Group has secured a landmark €300 million financing agreement with Credit funds managed by Ares Management Corporation (“Ares”), a leading global alternative investment manager.

This investment positions Amethyst as a leading player in the European oncology sector, as it continues to accelerate its expansion.

Facilities provided by Ares aim to fuel Amethyst’s ambitious growth plans, enabling investments in cutting-edge radiotherapy technologies and the establishment of new treatment centres across Europe. By broadening its footprint, Amethyst aims to bring innovative cancer care to more patients, addressing the escalating demand for accessible and high-quality oncological services.

This partnership with Ares marks a pivotal moment for Amethyst and the patients we serve,” said Stéphane Carré, CEO of Amethyst Radiotherapy. “With their support, we can intensify our efforts to deploy the latest treatment innovations and elevate the standard of cancer care throughout Europe.

Amethyst’s CFO, Andrew Nelson, echoed the sentiment, stating, “The facilities secured will support strategic acquisitions and capacity enhancement, positioning us firmly among the frontrunners to redefine the European cancer treatment landscape. We are delighted to be working with Ares, and we are confident that they will be an excellent partner for Amethyst in the years ahead.

Michael Dennis, Co-Head of European Credit at Ares Management, expressed confidence in Amethyst’s vision, noting, “We are thrilled to support Amethyst Radiotherapy in its vital mission to deliver high-quality, advanced cancer treatments across Europe. We have confidence in Amethyst’s strategic vision and long-term value creation potential, and we look forward to seeing the impactful advancements in healthcare outcomes that our partnership is expected to enable.

As major players in the private oncology sector vie for market share, Amethyst’s strategic financing deal with Ares solidifies its position as a formidable force, poised to drive transformative change in cancer care accessibility and quality throughout the region.

As featured in: and FinSMEs